Phillip Mertz
Director/Board Member chez ALPHA COGNITION INC.
Fortune : 728 377 $ au 31/03/2024
Profil
Phillip P.
Mertz is the founder of Secure Open Solutions.
He is currently the Chief Executive Officer at Subtle Technologies and the Director at Alpha Cognition, Inc. He previously worked as a Director at Alpha Cognition, Inc. Mr. Mertz received his undergraduate degree from Harvard University in 2006.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ALPHA COGNITION INC
1,43% | 29/08/2023 | 1 255 822 ( 1,43% ) | 728 377 $ | 31/03/2024 |
Postes actifs de Phillip Mertz
| Sociétés | Poste | Début |
|---|---|---|
| ALPHA COGNITION INC. | Director/Board Member | 22/03/2021 |
Anciens postes connus de Phillip Mertz
| Sociétés | Poste | Fin |
|---|---|---|
Alpha Cognition, Inc. /old/
 Alpha Cognition, Inc. /old/ Pharmaceuticals: MajorHealth Technology Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada. | Director/Board Member | - |
Formation de Phillip Mertz
| Harvard University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALPHA COGNITION INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Alpha Cognition, Inc. /old/
Alpha Cognition, Inc. /old/ Pharmaceuticals: MajorHealth Technology Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada. | Health Technology |
